Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients
Brief Summary: The purpose of this study is to compare the safety and efficacy of different induction agents (alemtuzumab, basiliximab or rabbit anti-thymocyte globulin) in renal transplant recipients treated with tacrolimus, mycophenolate mofetil (MMF) and a rapid steroid withdrawal.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: mycophenolate mofetil, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate mofetil, Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - single dose; Assigned to Arm(s): Group 1, Group 3 | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - 4 doses; Assigned to Arm(s): Group 2, Group 4 | Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4 | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4
B: Arm Label: Alemtuzumab High-Risk Patients; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus, Drug: alemtuzumab, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Conventional High-Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Drug: rabbit anti-thymocyte globulin, Drug: tacrolimus, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Alemtuzumab Low- Risk Patients; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus, Drug: alemtuzumab, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Conventional Low-Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Drug: basiliximab, Drug: tacrolimus, Drug: mycophenolate mofetil, Drug: steroids | Intervention Type: DRUG; Name: basiliximab; Assigned to Arm(s): Conventional Low-Risk Patients | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin; Assigned to Arm(s): Conventional High-Risk Patients | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients | Intervention Type: DRUG; Name: alemtuzumab; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients | Intervention Type: DRUG; Name: steroids; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Campath-1H | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Daclizumab | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Campath-1H; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): C
D: Arm Label: Campath-1H 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus | Arm Label: Campath-1H 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 20 mg | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 30 mg

Answer: B